Fresh frozen plasma reduces thrombin formation in newborn infants.
BACKGROUND
Newborn infants undergoing intensive care are at risk of bleeding and thrombotic complications. Fresh frozen plasma (FFP) is used in hope of preventing these complications, despite poorly defined effects on the coagulation system and lack of proven clinical efficacy.


OBJECTIVE
We prospectively evaluated coagulopathy and the effect of standardized amount of FFP transfusion (10 mL kg-1 + 4 mL in 2 h) on various coagulation markers in 33 newborn infants during the first 24 h of intensive care.


RESULTS
Increased levels of prothrombin fragment F1+2, thrombin-antithrombin complexes (TAT), and d-dimer were found prior to the transfusion in 97%, 81%, and 100% of the patients, respectively. FFP transfusion was associated with a decrease in F1+2 level in 26/32 (81%) of the patients. The extent of F1+2 decrease correlated with the pretransfusion F1+2 level (R = 0.65, P < 0.0001). The patient series was divided into two groups according to increasing pretransfusional F1+2 level: Group 1 (preFFP F1+2 > or = 2.35 nm, n = 16), Group 2 (F1+2 <2.35 nm, n = 16). In Group 1, F1+2 decreased on average 1.58 nm (P < 0.01) from the baseline during FFP transfusion but no significant change in the level of F1+2 during the transfusion was observed in Group 2. Pretransfusional levels of individual factors or prothrombin time (PT) did not correlate with the FFP-associated decrease in F1+2 level.


CONCLUSIONS
In the patients with the highest pretransfusional thrombin formation, FFP had an acute thrombin-reducing effect. Pretransfusion thrombin generation markers, rather than PT or individual pro- and anticoagulants, may be helpful in identifying the patient who will have measurable coagulational effects induced by FFP.
Hyytiäinen
S
S
Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland.
Syrjälä
M
M
Fellman
V
V
Heikinheimo
M
M
Petäjä
J
J
D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation; D005260:Female; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010949:Plasma; D011446:Prospective Studies; D013917:Thrombin / Q000096:biosynthesis*; D019851:Thrombophilia / Q000150:complications / Q000517:prevention & control*; D013927:Thrombosis / Q000150:complications / Q000517:prevention & control
D015415:Biomarkers; D013917:Thrombin